Physiomics PLC Conference Attendance and Presentation
20 Marzo 2019 - 1:02AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
20 March 2019
20(th) March 2019
Physiomics plc
("Physiomics") or ("the Company")
Conference attendance and presentation
Physiomics to present on personalised medicine and Virtual
Tumour(TM) developments at AACR 2019 meeting
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to announce that it is
participating in the American Academy of Cancer Research ("AACR")
Annual Meeting 2019, taking place in Atlanta, Georgia, 29(th) March
to 3(rd) April. The company will for the first time be presenting
on two new topics arising from client and grant funded
projects.
Physiomics will have a significant presence at the conference
including a stand in the main meeting hall (booth #1851). The
Company plans to use the opportunity of the conference to meet with
both current as well as potential future clients.
In addition, the Company will be presenting two original posters
in the session "PO.BSB02.01 - Convergence Science for Therapeutics
and Precision Medicine"-Section 30, scheduled 31(st) March 2019,
1:00 PM - 5:00 PM:
-- A precision dosing application for prostate cancer chemotherapy (Abstract #677)
This is our first tool based on AI (machine learning)
technologies. Currently dosing of docetaxel in prostate cancer is
based on population averages, leading to effective under or over
dosing in a significant number of patients. Our tool could, if
approved, provide information that could assist clinicians in
adapting chemotherapy dosing for individual patients. This offers
the possibility of enhancing both the safety and efficacy of an
existing standard of care without the costs typically associated
with a new pharmaceutical product.
-- Predicting the effect of radiotherapy on tumour growth
inhibition and time to progression in head and neck cancer
(Abstract #680)
Over recent years, driven by a number of actual client projects,
we have extended our Virtual Tumour(TM) technology from a tool
primarily used to predict preclinical tumour growth inhibition into
one that can also help clients understand the likely response to
their drug(s) in the clinic. The most recent evolution of Virtual
Tumour(TM) has been to enhance its ability to model the longer-term
re-growth of clinical tumours which can exhibit widely varying
times to re-growth/ progression following irradiation. As time to
progression is the strongest predictor of survival, we believe that
this enhanced capability increases the value of our predictions to
our clients.
According to AACR, it is the oldest and largest scientific
organisation in the world focused on every aspect of high-quality,
innovative cancer research. Its annual conference is attended by
representatives from public and private sector organisations from
the very small to the largest global players, with over 22,000
participants attending in 2018.
More information about the conference may be found at:
https://www.aacr.org/MEETINGS/PAGES/MEETINGDETAIL.ASPX?EVENTITEMID=174
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (NOMAD)
Katy Mitchell
James Sinclair-Ford
+44 (0) 161 832 2174
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry. The Company's Virtual Tumour(TM) technology
uses computer modelling to predict the effects of cancer drugs and
treatments to improve the success rate of drug discovery and
development projects while reducing time and cost. The predictive
capability of Virtual Tumour(TM) has been confirmed by over 70
projects, involving over 25 targets and 60 drugs, and has worked
with clients such as Merck KGaA, Merck & Co, Bayer and
Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKCDKOBKDOND
(END) Dow Jones Newswires
March 20, 2019 03:02 ET (07:02 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024